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Defining the antigenic changes that accompany malignant transformation and 
detecting whether these changes elicit immune recognition in the host of origin 
are  central  concerns  of tumor  immunology.  Serological  approaches  to  these 
issues have been vastly strengthened  with the advent of hybridoma technology 
(1).  Monoclonal  antibodies  are  providing  much  new  information  about  the 
antigenic structure of experimental and human cancers, and hybridoma analysis 
promises  to  be of great  value  in  dissecting  the  humoral  immune  response  to 
tumor antigens in tumor-bearing animals and humans. 
The problem with past efforts to resolve the question of tumor-related immune 
response in humans using conventional serology has had to do with the issue of 
specificity (2).  With  the exception of virus-related  antigens  on tumors such as 
Burkitt's  lymphoma  and  hepatoma  (3),  and  HLA antigens  and  blood  group 
antigens,  the nature and significance of other classes of human cancer antigens 
detected by human antibody are unknown. To assess the frequency and specificity 
of antibodies  reacting  with  surface  antigens  of human  cancer  cells,  we  have 
analyzed the autologous reactivity of sera from a series of patients with melanoma, 
astrocytoma, renal  cancer,  and  leukemia  (4-10).  Three  classes of antigens  de- 
tected by autologous antibody have been defined in this  way. Class  1 antigens 
are restricted  to autologous tumor cells,  not being detected on any other cell 
type,  normal  or  malignant.  Class  2  antigens  are  shared  antigens,  found  on  a 
proportion of allogeneic tumors as well as on autologous tumors; recent evidence 
indicates  that  some class 2  antigens  are autoantigenic  differentiation  antigens, 
since  they are  detected  on  a  restricted  range  of normal  tissues  (11).  Class  3 
antigens are widely distributed on normal and malignant cultures; these broadly 
represented antigens have not been extensively analyzed. Whereas class 3 reac- 
tivity is relatively common, antibodies to class  1 and class 2 antigens are found 
infrequently (~ 10% of patients). 
To extend these studies of bumoral immune reactions of cancer patients,  we 
have been exploring techniques for the production of human  monoclonal anti- 
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bodies using hybridoma methodology. Our initial experience with immunoglob- 
ulin-secreting clones derived from lymphocytes of patients with malignant mel- 
anoma is reported here. 
Materials and Methods 
Myeloma/Lymphoblastoid  Cell Lines.  The human myeloma cell line SKO-007 (12) was 
obtained from Beckton,  Dickinson &  Co.,  Sunnyvale, CA,  and  was  rendered free of 
mycoplasma contamination by Dr. J. Fogh, Sloan-Kettering Institute. SKO-007 secretes 
heavy chain and X light chain. The human LICR-LON-HMy2 (LICR-2) cell line (13) was 
obtained from Drs.  M.  O'Hare,  P.  Edwards,  and  M.  Neville,  London Branch of the 
Ludwig Institute for Cancer Research. This lymphoblastoid cell line secretes 3'1  heavy 
chain and ~ light chain and expresses Epstein-Barr virus (EBV)  l nuclear antigen (EBNA). 
The human lymphoblastoid cell line GM 4672, developed from the GM 1500 cell line by 
Croce et al. (14), was obtained from the Human Genetic Mutant Cell Repository, Institute 
of Medical Research, Camden, NJ. This cell line secretes ~  heavy chain and ~ light chain. 
The mouse myeloma cell line NS-1  (15) was obtained from Dr. U. H/immerling, Sloan- 
Kettering Institute. These cell lines were grown in  RPMI  1640 medium (containing 2 
mM glutamine, 1% nonessential amino acids, 100 U/ml penicillin, and 1 t~g/ml strepto- 
mycin), 7.5% (vol/voi) fetal bovine serum (FBS), and 20 t~g/ml 8-azaguanine. No growth 
occurred in medium containing 4 ×  10  -7 M aminopterin. 
Fusion Procedure.  Lymph node and tumor specimens from 33 patients with malignant 
melanoma  were  minced with  fine scissors  under  sterile conditions. The resulting cell 
suspension was washed twice in RPMI 1640 medium and used as the source oflymphocytes 
for fusion. Using lymph node and tumor-infiltrating lymphocytes, 36 fusions were per- 
formed with  LICR-2,  24 fusions with SKO-007, 8 with GM  4672, and  11  with NS-1. 
Peripheral blood iymphocytes from 25 melanoma patients were purified from heparinized 
venous blood by Ficoll-Hypaque (Pharmacia Fine Chemicals, Division of Pharmacia Inc., 
Piscataway, NJ) gradient centrifugation and 41 fusions performed with LICR-2, 32 with 
SKO-007, and  6  with  NS-1.  For further enrichment of B  cells,  T  lymphocytes were 
removed by rosetting with neuraminidase-treated sheep erythrocytes and centrifugation 
through a FicolI-Hypaque gradient. 
Lymphocytes and myeloma/lymphoblastoid cells were fused at ratios of 1:1 or 2:1 for 
3 min at 37°C in 0.2 ml 41.5% (wt/vol) polyethylene glycol (mol wt 4,000; J. T. Baker 
Chemical Co., Phillipsburg, N  J) dissolved in 15% (vol/vol) dimethyl sulfoxide. Between 2 
x  106 and 5 ×  107 lymphocytes were used in each fusion experiment. After fusion, cells 
were washed and left overnight in RPMI  1640 medium containing 15% FBS. The cells 
were  then  resuspended  in  RPMI  1640  medium  containing  15%  FBS,  2  ×  10  -4  M 
hypoxanthine, 4  x  10  -7 M aminopterin,  3.2  ×  10  -5 M thymidine, and 2  x  10  -5 M  2- 
mercaptoethanol (HAT medium) and plated at  105 cells per well into Costar 3696 96- 
well  plates  (Costar,  Cambridge,  MA),  preseeded  with  feeder  layers  prepared  from 
BALB/c or C57BL/6 splenocytes (105 cells/well) or peritoneal cells (1-2 ×  104 cells/ 
well). Cells were maintained in HAT medium for a minimum of 4 wk. Growing clones 
were defined as wells with continuing outgrowth more than 2 wk after fusion. Growing 
clones derived from fusions with LICR-2, SKO-007, and GM 4672 appeared between 3 
and 8 wk after fusion, while growing clones from fusions with NS-1 appeared between 2 
and  6  wk.  To compare the  results  of fusions with  different sources and  numbers  of 
lymphocytes and different myeloma/lymphoblastoid cell lines,  the fusion frequency was 
normalized and expressed as the median number of wells with growing clones per  107 
lymphocytes fused. 
Immunoglobulin  Assays.  Supernatants from wells containing growing clones were as- 
sayed for human ~, 3', or a  heavy chains by an enzyme-linked immunoassay. Costar 3696 
96-well plates were precoated with human IgG (50 #g/ml), IgA (50 ttg/ml), or IgM (10 
Abbreviations used in this paper:  EBNA,  Epstein-Barr virus nuclear antigen; EBV, Epstein-Barr 
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~g/ml) (Cappel Laboratories, Cochranville, PA) overnight at 4°C. The precoated wells 
were washed with phosphate-buffered saline (PBS) pH  7.5 and incubated with gamma 
globulin-free FBS (Gibco Laboratories, Grand Island, NY) for 30 rain. Goat anti-human 
#, 3', or a heavy chain antibodies linked to alkaline phosphatase (Sigma Chemical Co., St. 
Louis, MO), diluted 1:100, were mixed (1:1 vol/vol) with test supernatants or with IgG, 
IgA,  or  IgM  standards  diluted  in  RPMI  1640  medium  containing  15%  FBS  (final 
concentrations of standards were  10 ng/ml,  100  ng/ml, 1 #g/ml,  10 #g/ml, and  100 
#g/mi) and incubated for 90 rain. The mixtures were then transferred to precoated wells, 
incubated for 60 min, and washed with PBS. Alkaline phosphatase activity was detected 
using a p-nitrophenyldisodium phosphate substrate (Sigma Chemical Co.),  with changes 
in  optical  density measured  on  an  Artek  Model  210  Reader  (Artek  Systems Corp., 
Farmingdale, NY). The assay detected -<100 ng/mi of #, 3", or a  heavy chains and was 
specific for each Ig class over a range of <100 ng/ml to >100 #g/ml. The LICR-2 and 
GM 4672 parental lines produced 10-100 ng/mi and 10-500 ng/ml 3' chain, respectively. 
Neither #, 3", or a was detected in supernatants of SKO-007 or NS-1. 
Antibody Reactivity to Cell Surface and IntraceUular Antigens.  Supernatants from wells 
containing ---200 ng/ml Ig were screened for reactivity to cellular antigens using the 
following panel of 20 human tumor cell lines: melanomas (SK-MEL-13,  19, 23, 28, 29, 
37, 93,147, 165, and MeWo); malignant gliomas (U251 MG, SK-MG-3); epithelial cancers 
(SK-RC-7, SK-RC-9, BT-20, CAMA, 253J, HT29, OV2774, and Calu-1). To detect cell 
surface antigens, target cells were plated in Falcon 3034 plates (Falcon Labware, Oxnard, 
CA), and erythrocyte-rosetting assays for IgG (protein A [PAl assay) and IgM (immune 
adherence [IA] assay) were performed as previously described (5, 8). IgA antibodies were 
detected by indicator cells prepared by conjugating purified anti-human IgA (Accurate 
Chemical & Scientific Corp., Westbury, NY) to human erythrocytes with 0.01% chromium 
chloride. Absorption tests were performed according to previously described procedures 
(4). To detect intracellular antigens, supernatants were screened by indirect immunoflu- 
orescence tests using the same panel (see above). Target cells growing in Falcon 3034 
plates were fixed with a  1:1  (vol/vol) methanol/acetone mixture for 5  min at room 
temperature. The cells were incubated with supernatant for 1 h at room temperature, 
washed, and incubated with a 1:50 dilution of  gnat anti-human Ig conjugated to fluorescein 
isothiocyanate (FITC) (Cappel  Laboratories) for 45 min. Fluorescence was evaluated with 
a Leitz Dialux 20 microscope (E. Leitz, Inc., Rockleigh NJ). 
Chloroform~Methanol Extraction.  Cells were extracted with chloroform/methanol by 
previously described procedures (16). Antibody inhibition tests were carried out by mixing 
the cell  extract with antibody containing supernatant (diluted two dilutions below the 
endpoint), incubating for 1 h at 20°C, and testing for residual antibody reactivity using 
SK-RC-9 target cells. 
Results 
Cell Growth After Fusion of Lymphocytes with Myeloma/Lymphoblastoid  Cell Lines: 
Fusion  Frequency, Irnmunoglobulin  Production,  and  Clonal  Stability.  158  fusions 
were  performed  with  lymphocytes from  lymph  node,  tumor  infiltrate,  and 
melanoma patients.  Wells containing clonal outgrowth  peripheral blood of 52  2 
appeared  most frequently after fusion with the NS-1  mouse myeloma line (25 
clones per  107  lymphocytes fused) and the frequency of clonal outgrowth was 
similar with lymphocytes from lymph node and peripheral blood. From 3 to >25 
times lower frequency of growing clones was obtained after fusion with the three 
human  myeloma/lymphoblastoid cell  lines.  In  the  case  of lymphocytes from 
lymph  node,  fusions  with  LICR-2  resulted  in  a  higher  frequency  of clonal 
outgrowth (eight clones per  107 lymphocytes fused) than fusions with SKO-007 
2 Detailed results concerning fusion frequency and immunoglobulin production in relation to 
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or GM 4672 (one clone per 107 lymphocytes fused). Uniformly poor results were 
obtained in LICR-2 or SKO-007 fusions with peripheral blood as the source of 
lymphocytes (<1  clone per  10 7 lymphocytes fused). Enriching the B cell popula- 
tion  of peripheral  blood  lymphocytes by depleting T  cells before fusion with 
LICR-2 resulted in a 5 to >20 times higher frequency of growing clones. 
Immunoglobulin heavy chains #,  %  or a  were detected in  50-80%  of wells 
containing growing clones. The levels of Ig production ranged from 0.3  to 40 
t~g/ml and the relative proportion  of #-,  3'-, and a-positive wells varied from 
specimen to specimen.  No apparent relation was found between level and/or 
class of Ig production and the different fusion partners or sources of lymphocytes. 
The stability of Ig production by cells derived from fusions with  NS-1  and 
LICR-2 was examined by subculturing Ig  ÷ wells using a  limiting dilution tech- 
nique. Cells from 77%  (76/99) of Ig  ÷ wells from LICR-2 fusions continued to 
produce Ig after one subculture (between 2  and 3  mo after fusion), and 61% 
remained Ig  + after a  second subculture (at  3-4  mo).  A  lower percentage of 
mouse/human clones had persistent Ig production;  58%  (43/74)  of Ig  + wells 
from NS-1  fusions remained Ig  + after the first subculture (at 2 mo after fusion), 
and 30% were Ig  ÷ after the second subculture (at 3 mo). 
Immunoglobulin  Reactivity  with Cell Surface  Antigens:  Definition  of the Ma4 Anti- 
gen.  Supernatants  of  Ig  +  wells  were  tested  for  reactivity  with  cell  surface 
antigens by erythrocyte-rosetting assays using a panel of 20 cell lines, including 
10 melanomas, 2 gliomas, and 8 epithelial cancers (see Materials and Methods). 
Of 771  wells screened, positive reactions were observed with supernatants from 
6  wells (0.8%).  Efforts to  isolate antibody-secreting clones from these 6  wells 
resulted in  the establishment of a  cell line, designated Ma4,  that continued to 
produce an IgM antibody to a surface antigen of human cells. The Ma4 line was 
derived from a fusion of LICR-2 with lymphocytes from a regional lymph node 
of a  35-yr-old  man  with  recurrent  malignant  melanoma.  The  line  has  been 
subcloned (1 cell/well) four times and has maintained stable production of IgM 
(5 •g/ml)  and IgG (2/zg/ml) over a 12-too period. The Ma4 cell line is tetraploid 
by flow cytometry and contains only human chromosomes by karyotypic analysis. 
Analysis by sodium  dodecyl sulfate/polyacrylamide gel  electrophoresis shows 
that the Ma4 line secretes two distinct heavy chains,/z and % and light chains, K 
and ~,. 
Supernatants  from  cultures of the  Ma4  cell  line  were found  to  be  highly 
reactive with SK-RC-9 (an established cell line derived from human renal cancer) 
(Fig.  1). Reactivity was detected by IA assays for IgM antibody, but not by assays 
detecting IgA or IgG antibodies. (Serum from the patient providing lymphocytes 
used in the construction of the Ma4 cell line was unreactive [titer <1:2] with SK- 
RC-9 target cells by IA assay).  Fig.  2 illustrates IA tests with Ma4 supernatant 
on four other established human cell lines; reactions were seen with SK-LC-13, 
a cell line derived from lung cancer, and AIAb, a cell line derived from breast 
cancer, but not with two melanoma cell lines.  Fig.  3  demonstrates analysis of 
Ma4 antibody reactivity by absorption tests and Table I summarizes the results 
of direct tests and absorption analysis using a panel of 81 different cell types. 
The antigen detected by Ma4 antibody was found to heat stable (100°C for 
10 min) and resistant to treatment with trypsin and proteinase K. Chloroform/ HOUGHTON  ET  AL.  57 
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FIGURE  1.  Reactivity of Ma4 culture supernatant with SK-RC-9 renal cancer cells as deter- 
mined by three serological assays: (O) IA; (A) PA; (11) anti-IgA. 
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FIGURE 2.  Reactivity of Ma4 culture supernatant with four human cancer cell lines: SK-LC- 
13 (lung cancer) ([-1); AIAb (breast cancer) (n); SK-MEL-21 (O) and SK-MEL-37 (O) (melano- 
mas). Serological assay: IA. 
¢n 
Ioo 
(7) 
6 
r~ 
5o 
~  o  T  T  --i 
I1150  I1300  1/600  I112(X) 
Dilulion of  Mo4  Supernatanl 
FIGURE 3.  Absorption analysis of IA reactivity  of Ma4 culture supernatant (diluted  1:150) 
for SK-RC-9 renal cancer cells. Ma4 reactivity was absorbed by AIAb (breast cancer), SK-LC- 
13 (lung cancer), and SK-RC-9 (renal cancer). SK-MEL-21 (melanoma), SK-Ly-  16 (lymphoma), 
and sheep erythrocytes did not absorb Ma4 reactivity. (11) AIAb; (r-  0 SK-LC-13; (~7) SK-RC-9; 
((3) SK-Ly-16; (0) SK-MEL-21; (A) sheep erythrocytes; (A) unabsorbed Ma4 culture superna- 
tant. 
methanol  extracts  of the  Ma4-positive  cell  line  SK-RC-9  completely  inhibited 
Ma4 antibody reactivity. Extracts from Ma4-negative cell lines (253J and BT-20) 
had no inhibitory activity. 
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from the 771 Ig  + wells that were tested for reactivity to cell surface antigens (see 
above) were also tested for reactivity to intraceUular antigens by indirect immu- 
nofluorescence assays. 27 (3.5%) wells contained antibodies reacting with nuclei, 
nucleoli, cytoskeletal elements,  Golgi complex, and other cytoplasmic compo- 
nents. Cell lines from five of these wells have maintained stable antibody pro- 
duction  over a  5-8  mo observation  period.  All  five  cell  lines  produce  IgM 
antibody and were derived (by limiting dilutions) from fusions of lymph node 
lymphocytes. Antibodies  M307  and  M311  came from fusions with SKO-007; 
antibodies M304 and M305 from fusions with LICR-2; and antibody M54 from 
a  fusion with NS-1.  Antibody  M311  showed granular  staining of the  nucleus 
(Fig. 4A). Antibodies M305 and M307 reacted with cytoplasmic components in 
a  wide range of cultured cell types; M307  stained a  cytoskeletal network (Fig. 
4B) and staining with M305 showed a dense reticular pattern (Fig. 4C). Antibod- 
ies M304 and M54 also reacted with cytoplasmic components, but in the case of 
these antibodies reactions were restricted to certain cell types. Antibody M304 
reacted  with  cells of neuroectodermal  origin,  including astrocytomas  (9  of 9 
tested), melanomas (9 of 16 tested), neuroblastomas (1 of 3 tested), and normal 
melanocytes  (Figs.  4D  and  5A).  No  reactions  were  observed  with  epithelial 
cancers or with cultures of normal kidney or fibroblasts.  On the other hand, 
antibody M54 reacted primarily with epithelial cell lines, including breast cancers 
(four of five tested) and normal kidney epithelium (four of five tested) (Fig. 5B). 
Antibody M54 did not react with any cell line of neuroectodermal origin. 
Discussion 
In contrast to the success of hybridoma technology in the production of mouse 
and rat  monoclonal antibodies,  comparable studies with human antibody-pro- 
ducing hybrids have lagged behind. The general experience of many investiga- 
tors has been that fusion with drug-marked human myeloma or lymphoblastoid 
cell lines resulted in few clones with growth potential. Fusion of human lympho- 
cytes with mouse myeloma resulted in larger numbers of growing clones, but 
these appeared to be unstable with regard to Ig production. Recent studies (12- 
14, 18-23) and the results reported here indicate that methods for the construc- 
tion of Ig-secreting human/human hybrids or mouse/human hybrids have been 
considerably  improved and  are  now at  the  stage  that  a  fine  analysis  of the 
humoral immune response to cancer in humans can begin. Nonetheless, a number 
of technical questions remain to be clarified. Although Ig-secreting clones were 
obtained from fusions with the myeloma and lymphoblastoid lines used in this 
study  and  in  the  parallel  study  of Cote  et  al.  (23),  there  were  significant 
differences in the frequency of clonal outgrowth with each of the lines. In the 
case of the human lines, LICR-2 was clearly the superior partner. As the LICR- 
2 line is EBNA  +, and therefore presumably a  source of transforming EBV, the 
role of EBV in the better performance of LICR-2 needs to be analyzed. Although 
there is no doubt  that true hybrids can be obtained from LICR-2  fusions, as 
shown in this report and by Edwards et al. (13), Sikora et al. (20), and Cote et 
ai. (23), it remains to be determined what proportion of clones growing in Ig  + 
wells are  human/human  hybrids  and  what  proportion  are  EBV-transformed 60  HUMAN  MONOCLONAL  ANTIBODIES  TO  CELLULAR  ANTIGENS 
FIGURE 4.  Intracellular antigens detected  by IgM  antibodies in  supernatants of cultures 
derived from fusions of lymphocytes from lymph nodes of melanoma patients with LICR-2 
(M304 and M305 antibodies)and SKO-007 (M307 and M311 antibodies). (A) M311 detects a 
nuclear antigen (target SK-MEL-63 melanoma cell line); x  1,000; (B) M307 detects a cytoske- 
letal structure (target cell W1-38 fetal fibroblasts); x  400; (C) M305 detects a dense cytoplasmic 
network (target cell WI-38); x  200; (D) M304 detects a cytoplasmic antigen expressed by cells 
of neuroectodermal origin (target cell SK-MEL-93 melanoma cell line); x  400. 
lymphoblasts. Another problem is the lower frequency of clonal outgrowth after 
fusion of LICR-2 with peripheral blood lymphocytes. As peripheral blood is the 
most readily available source of iymphocytes from patients, this low yield of Ig- 
secreting clones will be a limiting factor in the application of LICR-2. There are 
several explanations for this observation, including (a) the low percentage of B 
cells in  peripheral  blood,  (b)  the possibility that  the differentiation  stage of B 
cells  in  the  peripheral  blood  is  not  optimal  for  hybrid  formation  or  hybrid 
stability or (c) destruction of hybrid cells by cytotoxic T  cells elicited by surface M
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antigens contributed by the LICR-2 partner.  If the latter possibility is involved 
in the low frequency of clonal outgrowth after LICR-2  fusion with peripheral 
blood lymphocytes, removal of T  cells before  fusion should increase  the  fre- 
quency of Ig-secreting clones. The outcome of initial experiments indicates that 
this may be the case.  Comparing results of fusion with the human myeloma/ 
lymphoblastoid cell lines to fusion with the NS-1 mouse myeloma showed that in 
each  instance,  including  fusions  with  peripheral  blood  lymphocytes,  the  fre- 
quency of outgrowth of NS-1-derived clones was substantially higher. In addition, 
mouse/human clones generally subcloned with higher efficiency than the hu- 
man/human clones. However,  Ig production by the mouse/human clones was 
less stable than the human clones. In a parallel but independent study from this 
laboratory  (23),  mouse/human clones were  found to be as  stable as human/ 
human  clones  and  mouse/mouse clones  with  respect  to  Ig  production.  The 
reason for this discrepancy between the two studies is being analyzed. 
Reactivity of Ig-containing supernatants with intracellular antigens was found 
to be significantly higher than reactivity with cell surface antigens. This finding 
could  have  several  explanations,  including  (a)  greater  polymorphism of cell 
surface antigens vs. intracellular antigens, requiring a larger variety of cell lines 
and cell types in  the screening panel  to identify antibodies  reacting with  cell 
surface antigens; (b) greater range of antigenic determinants within the cell than 
on the cell surface; (c) loss or low expression of certain cell surface antigens on 
cells  in  vitro  vs.  cells  in  vivo;  and  (d)  immunological tolerance  that  restricts 
autoantibodies to cell surface antigens to a  greater degree than to intracellular 
antigens. To pursue these points, it will be important to use noncultured cells as 
serological targets, to determine whether in vitro sensitization to surface antigens 
before fusion increases the frequency of surface antibodies, and to analyze the 
results  of fusions  with  lymphocytes from  patients  with  high-titered  antibody 
against known cell surface antigens, e.g., HLA or blood group antigens. 
The cell surface reactivity seen in our initial screening has not conformed to 
any known antigenic system or differentiation pathway. For example, specificity 
testing of the antibody produced by the Ma4 clone has not shown any recogniz- 
able reactivity pattern. The IgM antibody secreted by the Ma4 line reacted with 
19 of the 61  tumor cell lines tested, with no predilection for any particular cell 
type.  Similarly,  the  IgG antibody produced by a  stable mouse/human hybrid 
(Ri37) derived from the lymphocytes of a patient with breast cancer and reacting 
with a different set of tumor cell lines showed no differentiation-related pattern 
(23).  In contrast,  Irie et al. (24)  have analyzed a human antibody produced by 
EBV-transformed lymphocytes from a patient with melanoma that reacted with 
an antigen expressed by cells of neuroectodermal origin. Systematic analysis of 
a large number of cell surface-reactive human monoclonal antibodies, using both 
autologous as  well as allogeneic normal and malignant cells as targets,  should 
give insight  into  the  nature  of autoantigenic  surface  antigens and  determine 
whether any  have  the characteristics  of tumor-specific antigens.  Similarly,  the 
serological dissection of intracellular structures by human monoclonal antibodies HOUGHTON ET AL.  63 
permits a  new level  of precision  in  the study of autoimmune recognition of 
normal and malignant cells. 
Summary 
This  study  represents  an  initial  attempt  to  analyze  the  humoral  immune 
reactions  of patients  with  malignant  melanoma by  hybridoma  methodology. 
Using lymphocytes from regional  lymph nodes,  peripheral  blood  and  tumor 
infiltrates,  158  fusions were performed with SKO-007  (human myeloma line), 
LICR-LON-HMy2 (LICR-2), GM 4672 (human lymphoblastoid lines), or NS-1 
(mouse myeloma line). Fusion of lymph node lymphocytes with NS-1  resulted in 
a 3-4 times higher frequency of clones than fusion with LICR-2, and a  10 times 
higher  frequency  than  fusion  with  SKO-007  or  GM  4672.  In  the  case  of 
peripheral blood lymphocytes, fusion with NS-1 gave >25 times higher frequency 
of clones than fusion with LICR-2 or SKO-007. Production of human tL, ~,, or 
heavy chains was detected in 50-80%  of wells containing growing clones, and 
the levels of immunoglobulin ranged from 0.3 #g to 40 t~g/ml. NS-l-derived 
clones could  be  easily subcultured,  while  LICR-2  and  SKO-007  clones grew 
more slowly on subculturing. In this study, Ig secretion appeared to be a more 
stable property of LICR-2-derived clones than NS-l-derived clones. A panel of 
20  human  cancer cell  lines  was  used  to  screen  771  Ig-secreting cultures for 
antibody to  cell  surface or  intracellular antigens.  Reactivity with cell surface 
antigens was found infrequently (6 cultures), whereas reactivity with intracellular 
antigens  was  more  common  (27  cultures).  A  new  cell  surface  antigen  with 
properties of a glycolipid was defined with an IgM monoclonal antibody secreted 
by a tetraploid cell derived from a fusion of LICR-2 with lymphocytes from the 
axillary lymph node of a patient with melanoma. The hybrid cell line has been 
subcloned four times and secretes 5/~g IgM/ml. The antigen detected by this 
IgM antibody was found on 5 of 23 melanoma cell lines and 12 of 30 epithelial 
cancer cell lines. No reactions were found with 11 cultures derived from normal 
cells. Stable cell lines secreting human antibody that detected nuclei, nucleoli, 
cytoskeletal elements,  Golgi  complex,  or other cytoplasmic components were 
also  isolated  in  this  study.  One of these antibodies  detected an  intracellular 
antigen that is restricted to cells of neuroectodermal derivation, and a  second 
antibody reacted primarily with cells of epithelial origin. Using these methods to 
isolate and analyze human monoclonal antibody, it should now be possible  to 
define the repertoire of the humoral immune response to melanoma. 
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